501 AZD2796, a myeloid checkpoint inhibitor targeting LILRB2 that promotes pro-inflammatory responses by macrophages and enhances T cell anti-tumor activity

• Simon Dovedi,
• Mark Cobbold,
• Georgina Bowyer,
• Kathy Mulgrew,
• Fernanda Arnaldez,
• Des C Jones,
• Lorraine Irving,
• Becki Dudley,
• Marcin Wolny,
• Seraina Blümli,
• Ellie Chatzopoulou,
• Alan Sandercock,
• Stacy Pryts

Affiliations

Simon Dovedi

Aff161 grid.417815.e0000000104335842Medimmune Cambridge England UK

Mark Cobbold

2AstraZeneca, Gaithersburg, MD, USA

Georgina Bowyer

3University of Oxford (Jenner), United Kingdom

Kathy Mulgrew

2AstraZeneca, Gaithersburg, MD, USA

Fernanda Arnaldez

MacroGenics, Inc, Rockville, Maryland, USA

Des C Jones

1AstraZeneca, Cambridge, UK

Lorraine Irving

1AstraZeneca, Cambridge, UK

Becki Dudley

1AstraZeneca, Cambridge, UK

Marcin Wolny

1AstraZeneca, Cambridge, UK

Seraina Blümli

1AstraZeneca, Cambridge, UK

Ellie Chatzopoulou

1AstraZeneca, Cambridge, UK

Alan Sandercock

1AstraZeneca, Cambridge, UK

Stacy Pryts

2AstraZeneca, Gaithersburg, MD, USA